AC
SAGE

Avestar Capital’s Sage Therapeutics SAGE Stock Holding History

Avestar Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-98
Closed -$17K – 704
2019
Q2 		$17K Hold
98
– – 0.01% 419
2019
Q1 		$15K Buy
98
+21
+27% +$3.04K 0.01% 415
2018
Q4 		$7K Hold
77
– – ﹤0.01% 494
2018
Q3 		$10K Hold
77
– – 0.01% 468
2018
Q2 		$12K Buy
+77
New +$12.1K 0.01% 440

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Avestar Capital's SAGE Position: Q3 2019 in Review

Avestar Capital sold out of Sage Therapeutics (SAGE) in Q3 2019, closing a stake of 98 shares — an estimated $17K sold.

Avestar Capital first reported a position in SAGE in Q2 2018 and held it in 5 quarters. The position peaked at $17K in Q2 2019. 285 funds tracked by Wall St. Rank hold SAGE as of Q3 2019.

  • Avestar Capital reported no remaining Sage Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Avestar Capital sold 98 Sage Therapeutics shares in Q3 2019, an estimated $17K.
  • Avestar Capital first reported a position in Sage Therapeutics in Q2 2018 and held it in 5 quarters.
  • Avestar Capital's Sage Therapeutics position peaked at $17K in Q2 2019.
  • 285 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2019.

Based on Avestar Capital's 13F filing for Q3 2019, filed 14 Nov 2019.